Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (161-170 of 418) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 11, 2024
"Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized toolsEmilie Le Rhun, Michael Weller, Carey Anders, et al.
JAMA Oncology|July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical TrialsJames Larkin, Christopher D Lao, Walter J Urba, et al.
Health Policy (Amsterdam, Netherlands)|September 21, 2024
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019: A content analysisJames Larkin, Britta Matthes, Mohamed Azribi, et al.
Journal of Clinical Epidemiology|February 23, 2025
Shortcomings in reporting country-level participation in multicenter randomized controlled trials involving Ireland as a collaborating partner: a metaresearch studyJames Larkin, Uchechukwu Alanza, Vikneswaran Raj Nagarajan, et al.
EJNMMI Research|June 10, 2015
Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PETLaura M Kenny, Giampaolo Tomasi, Federico Turkheimer, et al.
The British Journal of Dermatology|May 16, 2024
Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitorsDaniel Yiu, Silvia Aguilar-Duran, Charlotte Edwards, et al.
Clinical and Experimental Dermatology|April 17, 2025
Grade 3 and Grade 4 Cutaneous toxicities in patients across multiple solid tumour types receiving checkpoint inhibitor therapy: An observational study. The experience of a single large specialist institutionZaina Sharif, James Larkin, Lisa Pickering, et al.
British Journal of Cancer|October 21, 2015
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanomaAnna Wilkins, Andrew Furness, Richard W Corbett, et al.
Health Policy (Amsterdam, Netherlands)|April 2, 2026
An essential medicines list in Ireland: A qualitative interview study of interest-holdersJames Larkin, Matthew Preteroti, Logan T Murry, et al.
BMC Cancer|December 21, 2018
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analysesIrina Proskorovsky, Agnes Benedict, Sylvie Negrier, et al.
Pageof 42

Showing results (161-170 of 418) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|July 11, 2024
"Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized toolsEmilie Le Rhun, Michael Weller, Carey Anders, et al.
JAMA Oncology|July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical TrialsJames Larkin, Christopher D Lao, Walter J Urba, et al.
Health Policy (Amsterdam, Netherlands)|September 21, 2024
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019: A content analysisJames Larkin, Britta Matthes, Mohamed Azribi, et al.
Journal of Clinical Epidemiology|February 23, 2025
Shortcomings in reporting country-level participation in multicenter randomized controlled trials involving Ireland as a collaborating partner: a metaresearch studyJames Larkin, Uchechukwu Alanza, Vikneswaran Raj Nagarajan, et al.
EJNMMI Research|June 10, 2015
Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PETLaura M Kenny, Giampaolo Tomasi, Federico Turkheimer, et al.
The British Journal of Dermatology|May 16, 2024
Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitorsDaniel Yiu, Silvia Aguilar-Duran, Charlotte Edwards, et al.
Clinical and Experimental Dermatology|April 17, 2025
Grade 3 and Grade 4 Cutaneous toxicities in patients across multiple solid tumour types receiving checkpoint inhibitor therapy: An observational study. The experience of a single large specialist institutionZaina Sharif, James Larkin, Lisa Pickering, et al.
British Journal of Cancer|October 21, 2015
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanomaAnna Wilkins, Andrew Furness, Richard W Corbett, et al.
Health Policy (Amsterdam, Netherlands)|April 2, 2026
An essential medicines list in Ireland: A qualitative interview study of interest-holdersJames Larkin, Matthew Preteroti, Logan T Murry, et al.
BMC Cancer|December 21, 2018
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analysesIrina Proskorovsky, Agnes Benedict, Sylvie Negrier, et al.
Pageof 42